JPH0536404B2 - - Google Patents
Info
- Publication number
- JPH0536404B2 JPH0536404B2 JP1037413A JP3741389A JPH0536404B2 JP H0536404 B2 JPH0536404 B2 JP H0536404B2 JP 1037413 A JP1037413 A JP 1037413A JP 3741389 A JP3741389 A JP 3741389A JP H0536404 B2 JPH0536404 B2 JP H0536404B2
- Authority
- JP
- Japan
- Prior art keywords
- pionin
- present
- antibacterial
- cosmetics
- paraben
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002537 cosmetic Substances 0.000 claims description 38
- DQYSALLXMHVJAV-UHFFFAOYSA-M 3-heptyl-2-[(3-heptyl-4-methyl-1,3-thiazol-3-ium-2-yl)methylidene]-4-methyl-1,3-thiazole;iodide Chemical compound [I-].CCCCCCCN1C(C)=CS\C1=C\C1=[N+](CCCCCCC)C(C)=CS1 DQYSALLXMHVJAV-UHFFFAOYSA-M 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 34
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 26
- 230000000845 anti-microbial effect Effects 0.000 claims description 4
- 230000000774 hypoallergenic effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 description 23
- 230000000844 anti-bacterial effect Effects 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 19
- 239000003242 anti bacterial agent Substances 0.000 description 18
- 239000003755 preservative agent Substances 0.000 description 17
- 239000006210 lotion Substances 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 230000002335 preservative effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- -1 masks Substances 0.000 description 8
- 230000002421 anti-septic effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 244000063299 Bacillus subtilis Species 0.000 description 5
- 235000014469 Bacillus subtilis Nutrition 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000589516 Pseudomonas Species 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 208000002440 photoallergic dermatitis Diseases 0.000 description 2
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229940074096 monoolein Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【発明の詳細な説明】
産業上の利用分野
本発明はピオニンおよびパラベンを含有する低
刺激性抗微生物用組成物および化粧料に関するも
のである。
従来の技術
従来、化粧品、医薬部外品などの皮膚に使用さ
れる化粧料は多くの場合、皮膚に馴染み易いよう
に設計されている。そのために微生物も繁殖し易
く、微生物で汚染された化粧料による被害が報告
されている。このような化粧料は多くの化合物の
複合剤であり、また近年の現象として数多くの植
物、動物からの天然抽出物などが有用成分として
配合され、基剤として微生物の繁殖にとつて好環
境を提供している。
化粧料には通常この汚染を防ぐために防腐・抗
殺菌剤が配合される。防腐・抗殺菌剤は細胞毒性
作用があつて微生物の繁殖を抑えたり（静菌作
用）、死滅させたり（殺菌作用）する作用を示す。
ところが防腐・抗殺菌剤は皮膚に対して接触皮膚
炎・光接触皮膚炎・アレルギー・光アレルギーな
どの副作用を誘発するなどの問題がある。勿論、
防腐・抗殺菌剤に限らず他の化粧品原料の中にも
副作用の心配なものもあり、化粧料の安全対策の
一つとして厚生省では「副作用が心配な成分につ
いては製品容器に成分を表示する」義務がもうけ
られている。（厚生省公示昭和55年薬発第125号）
このリストの中にはパラベン、安息香酸ナトリ
ウム、イソプロピルメチルフエノール、ウンデシ
レン酸、塩化ベンザルコニウム、デヒドロ酢酸、
レゾルシンなど化粧料に使われる防腐・抗殺菌剤
は全て記載されている。
ことに化粧品・医薬部外品などに巾広く繁用さ
れている代表的な防腐・抗殺菌剤であるパラベン
類は0.2〜2.0％で期待される効果はあるが、基剤
においては溶解性の悪いこと、パラベンアレルギ
ーがあること、パラベンによる皮膚傷害があるこ
となどの欠点が数多く報告されている。その配合
量を減らすと安全性も、溶解性も確保されるが抗
殺菌効果が極度に減少することから、仕方なく現
行濃度で使われているのが現状である。
これらの事から現時点では理想とする防腐・抗
殺菌剤はなく、この様に防腐・抗殺菌剤の最大許
容量で対応されていることが多い。
発明が解決しようとする課題
しかしながら化粧品や医薬部外品などの化粧料
は経度的に長年月にわたつて連用されること。ま
た化粧料は種々なる化合物の複合剤であるため、
諸因子により著しく防腐・抗殺菌効果を減衰する
場合が多い。例えばPHの影響、油水分配率による
もの、界面活性剤・高分子化合物への吸着などが
あり、その他に微生物の発育因子として利用され
る炭素源、窒素源、塩類、ビタミンなどで生育の
ための至適条件を与えている。
これらのことから少量で安全かつ広範囲の微生
物に有効な防腐・抗殺菌剤の選択を行なうことが
不可欠となつている。そのため単一化合物に頼る
のではなく、基剤条件に適応して２〜３種の組合
せにより少量化をはかり、安全面と有効性を満た
すことに注力されつつある。
理想的な防腐・抗殺菌剤は広い抗菌スペクト
ルであること少量で有効であること充分溶解
すること、生体に対して極力無毒・無刺激で安
全性の高いことなどがあげられる。業界において
は防腐・抗殺菌効果を落さずに、最も多用されて
いるパラベンの量を減少させることでより安全な
処法をあみ出すことは一つの大きな課題となつて
いる。
課題を解決するための手段
この課題を解決するために本発明者らはパラベ
ン配合量を減少させることとパラベンと相加・相
乗作用を示す物質の検策を行なつた。化粧料など
皮膚に直接接するものは安全でかつ化粧品への配
合が許可されている物質でなければならない。
そこで作用は勿論、安全面で数多くの研究が行
なわれ、その安全性から化粧料への配合物質の表
示義務を削除されているピオニンに着目して、そ
の併用を試みた。
ピオニン（感光素201号）は化粧品の特殊成分
として0.002％以下（医薬部外品として0.005％以
下）で広く配合されており、皮膚に対する安全性
も高く、成分表示義務のない原料である。ピオニ
ンは化粧品の生産過程での微生物汚染（一次汚
染）を防ぐ目的で防腐補助剤として使うものであ
るが、化粧品使用時での（二次汚染）殺菌剤とし
ては使われていない。
本発明者らはピオニンを0.001〜0.005重量％加
えることで、保有時・使用時での防腐・抗殺菌効
果を落すことなく、かつ併用するパラベン濃度を
従来の常用量の1/10量と大きく減衰させることを
発見して、本発明を完成した。
本発明により業界の課題であるパラベンの減量
が実現できたのである。
ここで「化粧料」とは商標法施行規則第四類
（石けん類、歯みがき、化粧品など）に規定する
ものを言う。
すなわち本発明はピオニンおよびパラベンを含
有することを特徴とする低刺激性抗微生物用組成
物および化粧料に関するものである。
本発明による低刺激性微生物用組成物はメイク
アツプ化粧品、軟膏、クリーム、ローシヨン、乳
液、パツク、石けんなどの基礎化粧品、コンタク
トレンズ洗浄剤、同保存剤、制汗用スプレーなど
として用いることが出来る。
作 用
本発明はピオニンを0.001〜0.005重量％配合
し、パラベンを0.02〜0.1％配合してなる２剤併
用のものである。
ピオニンはこの極微量濃度で殆んどの基剤に溶
解し、接触感作、光感作による異状発現はなく、
眼の粘膜刺激も至つて軽微であり、PH範囲として
生体に影響のない弱酸性から弱アルカリ制におい
て安定であり、諸種の界面活性剤中でも安定で何
れも効力の失活を見ない。またグラム陽性細菌に
も、グラム陰性細菌にも巾広い抗菌スペクトルを
有している。（日本香粧品科学会誌８（No.１）
P43、1984）
一方、パラベンは現在常用される量である0.1
〜1.0％の濃度では、化粧料基剤への溶解性は困
難か、もしくは不溶のこともある。そのため油水
分配率を油側に傾けるか、または界面活性剤によ
るミセル化溶解によることが試みられている。こ
れでは本来の防腐・抗殺菌効果は望めず基剤の処
法に一工夫も二工夫も必要となる。またパラベン
は経度吸収性があり、感作や接触皮膚炎などを起
し易い。このことは脂溶性配合することの危険性
を示唆するものである。
このパラベン配合量を1/10程度に減らすこと
は、溶解性も問題なく、添加濃度に応じた抗菌力
は期待できる。
この両者の併用は夫々の特性を生かして添付図
表を示すごとく期待以上に、化粧料汚染菌として
よく検出されるブドウ球菌、枯草菌、レンサ球
菌、線膿菌、大腸菌などに対して充分な抗殺菌力
が得られた。
また皮膚常在菌、暫定菌（黄色ブドウ球菌、表
皮ブドウ球菌、枯草菌など）など皮膚上の菌叢の
異状は皮膚傷害を起す元となり、傷害を起すと二
次感染症（黄色ブドウ球菌、線膿菌、アクネ菌な
ど）につながる。
化粧料はこれら皮膚を清浄化するとともに皮膚
菌叢の異状を起さないようにすることも大切な要
素である。ちなみにピオニンはニキビ起因菌であ
るアクネ菌に対して抗殺菌性を有し、ニキビの治
癒作用を有することもあり（日本香粧品科学会誌
７（No.３）P250、1983）化粧料への配合はこの
意味からも有用である。次に本発明の実施例およ
び効果をより詳しく説明する。
実施例
実施例 １
滅菌サンプル瓶に処法１のローシヨン20mlをと
り、これに前培養した化粧品由来の線膿菌液を
0.2ml（107／ml）を加え、ボルテツクスミキサー
にて充分混和して30℃の恒温器中に保存した。こ
の試料を毎日一定量採取し、界面活性剤
（Tweem80）カロ、燐酸緩衝液にて希釈したの
ち、その希釈液をハートインフイジヨン寒天培地
上に塗り拡げ、37℃、24時間培養を行ない、その
発生集落を計数して１ｇ（１ml）当りの生菌数に
より効果の判定を行なつた。
第１図に示すごとくピオニンおよびパラベンの
単独添加では抗殺菌性は弱いか、殆んど認められ
ないものが、本発明によるピオニンとパラベンの
同一濃度の併用添加組成物では24時間後測定で菌
叢は全く認められないすぐれた抗殺菌作用を示し
た。このことは線膿菌の107個の起始菌数と言う
多量の菌に対し、夫々の単独では抗菌力を示さな
い濃度で、２剤のすぐれた相乗効果を示し少量で
強い抗菌力をもつことを意味するものである。
実施例 ２
前培養した化粧品由来の大腸菌液を起始菌数
106／mlとなるように処法２のローシヨン（乳液）
に加え、実験施例１と同様に試験した。第１表に
示すごとく本発明による併用組成物は大腸菌に対
してもすぐれた効果を示した。
実施例 ３
前培養した化粧品由来の線膿菌液を起始菌数
107／mlとなるように処法３のクリームに加え、
実施例１と同様に静置培養を行ない試験した。そ
の結果を第２図に示す。この基剤組成中でも２剤
併用の効力が充分に見られた。
実施例 ４
前培養した化粧品由来の線膿菌液を起始菌数
107／mlとなるように処法４の化粧水に加え、実
施例１と同様に静置培養による試験を行なつた。
その結果を第３図に示す。本化粧水は大部分が水
であるが、湿潤剤として天然抽出物を添加したも
のである。
この影響か、基剤の大部分が水のため溶解性の
問題か、実施例１〜３の効力に比し、やゝ効力が
落ちるきらいはあるが、本発明である２剤の相加
効果は示している。
実施例 ５
前培養した化粧品由来の枯草菌液を起始菌数
106／mlとなるように、処法５のローシヨン（乳
液）に加え、実施例１と同様に試験した。
ここで枯草菌とは枯草、土壌、塵埃など自然界
に広く分布していることから空中浮遊細菌として
多く存在する。しかも芽胞をもち抵抗力の強い細
菌と言われている。
本実施例の結果、パラベン単独では抗菌力は弱
く、本発明で用いる低濃度では抗菌効果を示さな
いが、ピオニンは単剤でも0.003〜0.005％程度の
濃度では抗菌効果を示した。更に本発明である２
剤併用ではピオニン0.001〜0.002％とパラベン
0.03〜0.02％の極く低濃度域で充分な抗殺菌力を
示した（第４図）。
実施例 ６
空中落下細菌曝露試験
防腐剤、抗殺菌剤の一般的な感受性を検討する
場合、目的の薬剤を添加した平板上における落下
細菌の消長を観察する方法がとられる。
処法６の製品について、その20ｇ（ml）を滅菌
シヤーレにとり、室内に５時間曝露し、空中落下
細菌の負荷を行なつた後、30℃恒温器内にて一週
間（７日間）、一定量をハートインフイジヨン寒
天平板培地に取り培養した。
その結果、本発明の組成物を含まない無添加群
では何れも細菌集落を認めた。その内訳は芽胞
菌、グラム陰性菌、グラム陽性菌、カビであつ
た。それに比し本発明のピオニン、パラベンを含
む試験品はいづれも細菌集落を認めなかつた。
以下に処法について説明する。
処法１ ローシヨン
油性成分マイクロクリスタリンワツクス
1.0重量％
ミツロウ 2.0
ラノリン 2.0
流動パラフイン 30.0
乳化剤ソルビタンセスキオレイン酸エステル
4.0
ポリオキシエチレンソルビタンモノオ
レイン酸エステル（20E.O.）
1.0
ステアリン酸アルミニウム 0.2
香 料 0.4
防腐・抗殺菌剤 本発明組成物
保湿剤 グリセリン 8.0
精製水 51.4
処法２ ローシヨン
油性成分ステアリン酸 2.0％
セタノール 1.5
ワセリン 3.0
ラノリンアルコール 2.0
流動パラフイン 10.0
乳化剤ポリオキシエチレンモノオレイン酸エステ
ル（10E.O.） 2.0
香 料 0.5
防腐・抗殺菌剤 本発明組成物
保湿剤グリセリン 3.0
プロピレングリコール 5.0
アルカリ トリエタノールアミン 1.0
精製水 70.0
処法３ コールドクリーム
油性成分ベオニールアルコール酸 3.0％
ミツロウ 4.0
パラフインワツクス 2.5
流動パラフイン 48.0
脂肪酸グリセリド 2.0
乳化剤ポリエチレングリコール脂肪酸エステル
0.5
グリセリン脂肪酸エステル 1.0
ポリオキシエチレンソルビタンモノラ
ウリン酸エステル（20E.O.） 2.5
ポリオキシエチレンアルキルエーテル
1.0
ホウ砂 0.3
香 料 0.2
防腐・抗殺菌剤 本発明組成物
保湿剤ヒアルロンエキス 0.5
精製水 34.5
処法４ 化粧水
エタノール 3.0
可溶化剤ポリオキシエチレンラウリルエーテル
0.3
保湿剤グリセリン 0.5
ピロリドンカルボン酸ナトリウム
1.0
緩衝剤クエン酸 0.1
クエン酸ナトリウム 0.2
着香料 適 量
湿潤剤ビフイズス菌エキス 1.0
ヒアルロンエキス 0.5
防腐・抗殺菌剤 本発明組成物
精製水 93.4
処法５ ローシヨン
油性成分スクワラン 5.0％
ワセリン 2.0
ミツロウ 0.5
ラノリンアルコール 1.5
ステアリン酸 0.3
乳化剤ソルビタンセスキオレイン酸エステル
0.8
ポリオキシエチレンオレイルエーテル
（20E.O.） 1.2
香 料 0.2
防腐・抗殺菌剤 本発明組成物
保湿剤グリセリン 2.0
プロピレングリコール 3.0
増粘剤 カルボキシビニールポリマー 0.1
精製水 83.4
処法６ コンタクトレンズ洗浄液
プルラン 2.0％
ポリオキシエチレンラウリルエーテル 0.5
塩化ナトリウム 0.6
防腐・抗殺菌剤 本発明組成物
精製水 96.9
効 果
パラベンは化粧料分野で現在防腐・抗殺菌剤と
して最も繁用されているが、前述のごとく現在常
用の量では多くの欠点を有し、溶解の点、皮膚刺
激、生体への経度吸収などで問題が多い。
ピオニンは0.002〜0.005％と言う極く微量で、
抗菌効果があり、低毒性で安全性の高い化合物で
ある。
本発明はこの２つの化合物を併用し、パラベン
配合量を大きく減衰することで、化粧料などの使
用上の安全性を大きく亢進させ、化粧料などの製
造過程、保存時での対微生物対策と製品の安定性
の向上に大きく寄与することが可能となつた。
【表】
＊；処法２のローシヨン
DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application The present invention relates to hypoallergenic antimicrobial compositions and cosmetics containing pionin and parabens. BACKGROUND ART Conventionally, cosmetics, quasi-drugs, and other cosmetics used for the skin are often designed to be easily blended into the skin. Therefore, microorganisms are likely to grow, and damage caused by cosmetics contaminated with microorganisms has been reported. Such cosmetics are composite agents of many compounds, and as a recent phenomenon, natural extracts from many plants and animals are blended as useful ingredients, and as a base, they provide a favorable environment for the growth of microorganisms. providing. Cosmetics usually contain preservatives and antibacterial agents to prevent this contamination. Preservatives and antibacterial agents have a cytotoxic effect and exhibit the effect of suppressing the proliferation of microorganisms (bacteriostatic effect) or killing them (sterilizing effect).
However, antiseptic and antibacterial agents have problems such as inducing side effects on the skin such as contact dermatitis, photocontact dermatitis, allergies, and photoallergy. Of course,
In addition to preservatives and antibacterial agents, there are also concerns about side effects among other cosmetic ingredients, and as one of the safety measures for cosmetics, the Ministry of Health and Welfare recommends that ingredients with concerns about side effects be listed on the product container. ” An obligation has been created. (Ministry of Health and Welfare Public Notice No. 125 of 1980) This list includes parabens, sodium benzoate, isopropylmethylphenol, undecylenic acid, benzalkonium chloride, dehydroacetic acid,
All preservatives and antibacterial agents used in cosmetics, such as resorcinol, are listed. In particular, parabens, which are typical preservatives and antibacterial agents widely used in cosmetics and quasi-drugs, have the expected effect at 0.2 to 2.0%, but their solubility in the base Many disadvantages have been reported, including being allergic to parabens, and skin damage caused by parabens. Reducing the amount added ensures safety and solubility, but the antibacterial effect is extremely reduced, so currently, it has no choice but to be used at its current concentration. For these reasons, there is currently no ideal preservative/antibacterial agent, and as described above, the maximum allowable amount of the preservative/antibacterial agent is often used. Problems to be Solved by the Invention However, cosmetics such as cosmetics and quasi-drugs are used continuously for many years. In addition, since cosmetics are composite agents of various compounds,
In many cases, the antiseptic and antibacterial effects are significantly reduced by various factors. For example, there are effects such as pH, oil/water partition ratio, adsorption to surfactants and polymer compounds, and carbon sources, nitrogen sources, salts, vitamins, etc. used as growth factors for microorganisms. Provides optimal conditions. For these reasons, it has become essential to select antiseptic and antibacterial agents that are safe in small amounts and effective against a wide range of microorganisms. Therefore, instead of relying on a single compound, efforts are being made to reduce the amount by combining two to three types according to the base conditions and to satisfy safety and effectiveness. The ideal antiseptic/antibacterial agent should have a broad antibacterial spectrum, be effective in small amounts, be sufficiently soluble, be as nontoxic and nonirritating to living organisms, and be highly safe. A major challenge in the industry is to create safer formulations by reducing the amount of parabens, which are the most commonly used substances, without sacrificing their antiseptic and antibacterial effects. Means for Solving the Problems In order to solve this problem, the present inventors reduced the amount of parabens added and examined substances that exhibit additive or synergistic effects with parabens. Cosmetics and other substances that come into direct contact with the skin must be safe and must be approved for inclusion in cosmetics. Therefore, we focused on pionin, which has undergone numerous studies on safety as well as its effects, and whose labeling requirements for ingredients in cosmetics have been removed due to its safety, and attempted to use it in combination. Pionin (Photosensor No. 201) is widely used as a special ingredient in cosmetics at 0.002% or less (0.005% or less as a quasi-drug), is highly safe for the skin, and is a raw material that is not required to be labeled as an ingredient. Pionin is used as a preservative aid to prevent microbial contamination (primary contamination) during the production process of cosmetics, but it is not used as a disinfectant during cosmetic use (secondary contamination). By adding 0.001 to 0.005% by weight of pionin, the present inventors succeeded in increasing the concentration of parabens used in combination to 1/10 of the conventional regular dose without reducing the antiseptic and antibacterial effects during storage and use. The present invention was completed by discovering that it can attenuate. The present invention has made it possible to reduce the amount of parabens, which has been an issue in the industry. Here, "cosmetics" refers to those stipulated in Class 4 of the Trademark Law Enforcement Regulations (soaps, toothpaste, cosmetics, etc.). That is, the present invention relates to hypoallergenic antimicrobial compositions and cosmetics characterized by containing pionin and parabens. The hypoallergenic composition for microorganisms according to the present invention can be used as makeup cosmetics, basic cosmetics such as ointments, creams, lotions, milky lotions, masks, and soaps, contact lens cleaning agents, preservatives, antiperspirant sprays, and the like. Effects The present invention is a two-drug combination product containing 0.001 to 0.005% by weight of pionin and 0.02 to 0.1% of paraben. Pionin dissolves in most bases at this extremely small concentration, and does not cause any abnormalities due to contact sensitization or photosensitization.
It causes minimal irritation to the mucous membranes of the eye, and is stable in the pH range from weakly acidic to weakly alkaline, which has no effect on living organisms, and is stable even in various surfactants, with no loss of efficacy in any of them. It also has a broad antibacterial spectrum against both Gram-positive and Gram-negative bacteria. (Journal of the Japanese Cosmetic Science Society 8 (No. 1)
P43, 1984) On the other hand, parabens are presently used in an amount of 0.1
At concentrations of ~1.0%, solubility in cosmetic bases is difficult or even insoluble. Therefore, attempts have been made to tilt the oil-water distribution ratio toward the oil side or to use surfactants to form and dissolve micelles. In this case, the original antiseptic and antibacterial effects cannot be expected, and it is necessary to devise one or two ingenuity in the formulation of the base. Parabens are also absorbable over time and can easily cause sensitization and contact dermatitis. This suggests the danger of incorporating fat-soluble ingredients. By reducing the amount of paraben added to about 1/10, there will be no problem with solubility, and antibacterial activity can be expected depending on the added concentration. The combination of these two takes advantage of their respective characteristics, and as shown in the attached diagram, provides sufficient protection against Staphylococcus, Bacillus subtilis, Streptococcus, Pseudomonas Streptococcus, Escherichia coli, etc., which are commonly detected as cosmetic contaminants. Sterilizing power was obtained. In addition, abnormalities in the bacterial flora on the skin, such as resident bacteria and provisional bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, etc.), can cause skin injuries, and if injuries occur, secondary infections (Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, etc.) This leads to Pseudomonas aeruginosa, P. acnes, etc.). It is important for cosmetics to cleanse the skin and to prevent abnormalities in the skin flora. By the way, pionin has antibacterial properties against acne-causing bacteria, P. acnes, and can also have an acne-healing effect (Journal of the Japanese Cosmetic Science Society 7 (No. 3) P250, 1983) and is used in cosmetics. is also useful in this sense. Next, embodiments and effects of the present invention will be described in more detail. Examples Example 1 Put 20 ml of the lotion of Method 1 into a sterile sample bottle, and add the pre-cultured cosmetic-derived Pseudomonas liquid to it.
0.2 ml (10 7 /ml) was added, thoroughly mixed with a vortex mixer, and stored in a thermostat at 30°C. A certain amount of this sample was collected every day, diluted with surfactant (Tweem80) Calo, and phosphate buffer, and the diluted solution was spread on a heart infusion agar medium and cultured at 37°C for 24 hours. The resulting colonies were counted and the effectiveness was determined based on the number of viable bacteria per 1 g (1 ml). As shown in Figure 1, when pionin and paraben are added alone, the antibacterial effect is weak or almost non-existent, but when the combined addition composition of pionin and paraben at the same concentration according to the present invention is used, the antibacterial effect is observed after 24 hours. The flora showed excellent antibacterial activity, which was not observed at all. This shows that the two agents have an excellent synergistic effect against a large number of Pseudomonas aeruginosa bacteria (10 7 starting bacteria) at concentrations that do not exhibit antibacterial activity when used alone. It means to have. Example 2 Calculating the number of starting bacteria from a pre-cultured cosmetic-derived E. coli solution
10 6 lotion (emulsion) of formula 2 so that it is 10 6 /ml
In addition, tests were conducted in the same manner as in Experimental Example 1. As shown in Table 1, the combination composition according to the present invention also showed excellent effects against E. coli. Example 3 Determination of the number of starting bacteria from the pre-cultured cosmetic-derived Pseudomonas fluid
Add to the cream of Prescription 3 so that the concentration is 10 7 /ml,
A static culture was performed and tested in the same manner as in Example 1. The results are shown in FIG. Even with this base composition, the effectiveness of the combination of the two drugs was sufficiently observed. Example 4 Initial bacterial count of pre-cultured cosmetic-derived Pseudomonas fluid
It was added to the lotion of Treatment 4 at a concentration of 10 7 /ml, and a static culture test was conducted in the same manner as in Example 1.
The results are shown in FIG. This lotion is mostly water, but natural extracts are added as humectants. The additive effect of the two agents of the present invention may be due to this effect or because the majority of the base is water, resulting in a solubility problem, but the efficacy tends to be slightly lower than that of Examples 1 to 3. shows. Example 5 Initial bacterial count of pre-cultured Bacillus subtilis solution derived from cosmetics
It was added to the lotion (milk lotion) of Prescription 5 so that the concentration was 10 6 /ml and tested in the same manner as in Example 1. Here, Bacillus subtilis is widely distributed in the natural world such as dried grass, soil, and dust, and therefore exists in large numbers as an airborne bacterium. Moreover, it is said to be a highly resistant bacterium that has spores. As a result of this example, paraben alone has weak antibacterial activity and does not show antibacterial effect at the low concentration used in the present invention, but pionin alone showed antibacterial effect at a concentration of about 0.003 to 0.005%. Furthermore, the present invention 2
Pionin 0.001-0.002% and parabens are used in combination with drugs.
It showed sufficient antibacterial activity at extremely low concentrations of 0.03 to 0.02% (Figure 4). Example 6 Airborne Bacteria Exposure Test When examining the general susceptibility of preservatives and antibacterial agents, a method is used to observe the growth of fallen bacteria on a flat plate to which the target agent has been added. Regarding the product of Formulation 6, 20g (ml) of it was placed in a sterilized petri dish, exposed indoors for 5 hours to load with airborne bacteria, and then kept in a constant temperature chamber at 30°C for one week (7 days). An aliquot was taken and cultured on a heart infusion agar plate medium. As a result, bacterial colonies were observed in all the additive-free groups that did not contain the composition of the present invention. The breakdown was spore-forming bacteria, gram-negative bacteria, gram-positive bacteria, and molds. In contrast, no bacterial colonies were observed in any of the test products containing pionin and paraben of the present invention. The treatment method will be explained below. Treatment method 1 Lotion oil-based ingredient microcrystalline wax
1.0% by weight Beeswax 2.0 Lanolin 2.0 Liquid paraffin 30.0 Emulsifier Sorbitan sesquioleate
4.0 Polyoxyethylene sorbitan monooleate (20E.O.)
1.0 Aluminum stearate 0.2 Fragrance 0.4 Preservative/antibacterial agent Moisturizing agent of the composition of the present invention Glycerin 8.0 Purified water 51.4 Prescription 2 Lotion oil component Stearic acid 2.0% Setanol 1.5 Vaseline 3.0 Lanolin alcohol 2.0 Liquid paraffin 10.0 Emulsifier Polyoxyethylene monoolein Acid ester (10E.O.) 2.0 Fragrance 0.5 Preservative/antibacterial agent Moisturizing agent of the composition of the present invention Glycerin 3.0 Propylene glycol 5.0 Alkali Triethanolamine 1.0 Purified water 70.0 Method 3 Cold cream oily ingredient Beonyl alcoholic acid 3.0% Beeswax 4.0 Paraffin wax 2.5 Liquid paraffin 48.0 Fatty acid glyceride 2.0 Emulsifier polyethylene glycol fatty acid ester
0.5 Glycerin fatty acid ester 1.0 Polyoxyethylene sorbitan monolaurate (20E.O.) 2.5 Polyoxyethylene alkyl ether
1.0 Borax 0.3 Fragrance 0.2 Preservative/antibacterial agent Moisturizing agent of the composition of the present invention Hyaluronic extract 0.5 Purified water 34.5 Prescription 4 Lotion Ethanol 3.0 Solubilizer polyoxyethylene lauryl ether
0.3 Moisturizer glycerin 0.5 Sodium pyrrolidone carboxylate
1.0 Buffer Citric acid 0.1 Sodium citrate 0.2 Flavoring agent Appropriate amount Wetting agent Bifidobacterium extract 1.0 Hyaluronic acid extract 0.5 Preservative/antibacterial agent Purified water of the composition of the present invention 93.4 Prescription 5 Lotion oily component squalane 5.0% Vaseline 2.0 Beeswax 0.5 Lanolin alcohol 1.5 Stearic acid 0.3 Emulsifier Sorbitan sesquioleate
0.8 Polyoxyethylene oleyl ether (20E.O.) 1.2 Fragrance 0.2 Preservative/antibacterial agent Moisturizing agent of the composition of the present invention Glycerin 2.0 Propylene glycol 3.0 Thickener Carboxyvinyl polymer 0.1 Purified water 83.4 Prescription 6 Contact lens cleaning liquid Pullulan 2.0 % Polyoxyethylene lauryl ether 0.5 Sodium chloride 0.6 Preservative/antibacterial agent Purified water of the composition of the present invention 96.9 Effect Parabens are currently the most commonly used preservative/antibacterial agent in the cosmetics field; It has many drawbacks in terms of dissolution, skin irritation, and long-term absorption into living organisms. Pionin is present in extremely small amounts of 0.002 to 0.005%.
It is a highly safe compound with antibacterial effects and low toxicity. The present invention uses these two compounds in combination to significantly reduce the amount of parabens added, thereby greatly increasing the safety of cosmetics and other products, and improving anti-microbial measures during the manufacturing process and storage of cosmetics. This has made it possible to greatly contribute to improving product stability. [Table] *; Lotion of method 2
第１図処法１のローシヨン中における本発明組
成物と比較剤の線膿菌に対する抗殺菌効果。
Ａ；本発明組成物（ピオニン0.005％、パラベ
ン0.05％）、Ｂ；本発明組成物（ピオニン0.004
％、パラベン0.07％）、Ｃ；本発明組成物（ピオ
ニン0.003％、パラベン0.1％）、Ｄ；比較剤（無
添加）、Ｅ；比較剤（パラベン0.05％）、Ｆ；比較
剤（ピオニン0.005％）、Ｇ；比較剤（パラベン
0.1％）。
第２図処法３のクリーム中における本発明組成
物と比較剤の線膿菌に対する抗殺菌効果。
Ａ；本発明組成物（ピオニン0.005％、パラベ
ン0.02％）、Ｂ；本発明組成物（ピオニン0.002
％、パラベン0.05％）、Ｃ；本発明組成物（ピオ
ニン0.002％、パラベン0.07％）、Ｄ；本発明組成
物（ピオニン0.002％、パラベン0.03％）、Ｅ；比
較品（無添加）、Ｆ；比較品（パラベン0.1％）、
Ｇ；比較品（ピオニン0.005％）。
第３図処法４の化粧水中における本発明組成物
と比較剤の線農菌に対する抗殺菌効果。
Ａ；本発明組成物（ピオニン0.002％、パラベ
ン0.1％）、Ｂ；本発明組成物（ピオニン0.005％、
パラベン0.07％）、Ｃ；本発明組成物（ピオニン
0.003％、パラベン0.07％）、Ｄ；比較剤（無添
加）、Ｅ；比較剤（ピオニン0.002％）、Ｆ；比較
品（パラベン0.05％）、Ｇ；比較品（ピオニン
0.005％）。
第４図処法５のローシヨン中における本発明組
成物と比較剤の線膿菌に対する抗殺菌効果。
Ａ；本発明組成物（ピオニン0.02％、パラベン
0.02％）、Ｂ；本発明組成物（ピオニン0.001％、
パラベン0.03％）、Ｃ；比較剤（ピオニン0.003
％）、Ｄ；比較剤（無添加）、Ｅ；比較剤（パラベ
ン0.05％）、Ｆ；比較剤（パラベン0.1％）。
Figure 1 shows the antibacterial effect of the composition of the present invention and the comparative agent against Pseudomonas aeruginosa in the lotion of Treatment 1. A: Composition of the present invention (0.005% pionin, 0.05% paraben), B: Composition of the present invention (0.004% pionin)
%, paraben 0.07%), C: Composition of the present invention (pionin 0.003%, paraben 0.1%), D: Comparative agent (no addition), E: Comparative agent (paraben 0.05%), F: Comparative agent (pionin 0.005%) ), G; comparative agent (paraben
0.1%). Figure 2 shows the antibacterial effects of the composition of the present invention and a comparative agent against Pseudomonas aeruginosa in the cream of Treatment 3. A: Composition of the present invention (0.005% pionin, 0.02% paraben), B: Composition of the present invention (0.002% pionin)
%, paraben 0.05%), C; composition of the present invention (pionin 0.002%, paraben 0.07%), D; composition of the present invention (pionin 0.002%, paraben 0.03%), E; comparative product (no additives), F; Comparative product (paraben 0.1%),
G: Comparative product (pionin 0.005%). FIG. 3 shows the antibacterial effects of the composition of the present invention and a comparative agent in the lotion of Treatment Method 4 against Streptococcus aeruginosa. A: Composition of the present invention (0.002% pionin, 0.1% paraben), B: Composition of the present invention (0.005% pionin,
Paraben 0.07%), C; Composition of the present invention (Pionin
0.003%, paraben 0.07%), D; comparative agent (no additives), E; comparative agent (pionin 0.002%), F; comparative product (paraben 0.05%), G; comparative product (pionin
0.005%). Figure 4 shows the antibacterial effect of the composition of the present invention and the comparative agent against Pseudomonas aeruginosa in the lotion of Treatment 5. A: Composition of the present invention (0.02% pionin, paraben
0.02%), B; composition of the present invention (pionin 0.001%,
Paraben 0.03%), C; Comparative agent (Pionin 0.003
%), D: Comparative agent (no addition), E: Comparative agent (paraben 0.05%), F: Comparative agent (paraben 0.1%).
Claims (1)
徴とする低刺激性抗微生物用組成物。 ２ ピオニン0.001〜0.005重量％およびパラベン
0.02〜0.1重量％を含有することを特徴とする特
許請求の範囲第１項記載の組成物。 ３ ピオニンおよびパラベンを含有することを特
徴とする化粧料。[Scope of Claims] 1. A hypoallergenic antimicrobial composition characterized by containing pionin and paraben. 2 Pionin 0.001-0.005% by weight and parabens
The composition according to claim 1, characterized in that it contains 0.02 to 0.1% by weight. 3. A cosmetic containing pionin and paraben.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1037413A JPH02215706A (en) | 1989-02-16 | 1989-02-16 | Antimicrobial composition and cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1037413A JPH02215706A (en) | 1989-02-16 | 1989-02-16 | Antimicrobial composition and cosmetic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH02215706A JPH02215706A (en) | 1990-08-28 |
| JPH0536404B2 true JPH0536404B2 (en) | 1993-05-31 |
Family
ID=12496838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1037413A Granted JPH02215706A (en) | 1989-02-16 | 1989-02-16 | Antimicrobial composition and cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH02215706A (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4734293B2 (en) * | 1998-02-24 | 2011-07-27 | 株式会社林原生物化学研究所 | Antiseptic disinfectant and human body composition |
| JP5302239B2 (en) * | 1998-02-24 | 2013-10-02 | 株式会社マンダム | Antiseptic disinfectant and human body composition |
| JP2001048781A (en) * | 1999-08-09 | 2001-02-20 | Taisho Pharmaceut Co Ltd | Composition for external use |
| JP5145214B2 (en) * | 2006-05-11 | 2013-02-13 | 株式会社林原 | Disinfectant / preservative |
| IL270898B2 (en) * | 2017-06-02 | 2023-04-01 | Zurex Pharma Inc | Low-alcohol and sterilizable antimicrobial compositions and use thereof |
-
1989
- 1989-02-16 JP JP1037413A patent/JPH02215706A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH02215706A (en) | 1990-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6187327B1 (en) | Antimicrobial sanitizing lotion with skin protection properties | |
| US6617294B2 (en) | Waterless sanitizing hand cleanser | |
| JPH07330505A (en) | Antimicrobial composition | |
| EP1699529A1 (en) | Antimicrobial compositions containing an aromatic carboxylic acid and a hydric solvent | |
| JPH06509564A (en) | antibacterial mixture | |
| JP5637987B2 (en) | Preservative composition | |
| WO2007103441A2 (en) | Antimicrobial esters | |
| JP2011074082A (en) | Antiseptic sterilizer and composition for application to human body | |
| KR102272901B1 (en) | Composition for external application to the skin containing meso-2,3-butanediol as a preservative | |
| JP5346455B2 (en) | Antibacterial detergent composition | |
| JPH06157278A (en) | Skin external preparation for acne vulgaris | |
| JP6971518B2 (en) | Antibacterial composition containing thymol, terpineol, and cationic phospholipids | |
| JPH0536404B2 (en) | ||
| JP4734293B2 (en) | Antiseptic disinfectant and human body composition | |
| JP4999321B2 (en) | Drugs containing antiseptic disinfectant and antiseptic disinfection method | |
| KR102482158B1 (en) | gel composition for disinfection and manufacturing method thereof | |
| KR102241761B1 (en) | A composition having a fast-acting sterilizing effect at room temperature | |
| JP4541661B2 (en) | Disinfecting and / or disinfecting composition | |
| JP2010209116A (en) | Antiseptic bactericide and cosmetic composition | |
| RU2409367C2 (en) | Prophylactic agent for skin with antituberculous effect | |
| KR20190056979A (en) | Novel use | |
| KR102442630B1 (en) | Disinfectant composition targeting nosocomial pathogens based on low-concentration ethanol and natural antimicrobial synergism | |
| JP7475210B2 (en) | Leave-on disinfectant composition | |
| JPH11199476A (en) | Composition for disinfection and/or sterilization | |
| KR100822416B1 (en) | Fragrance composition with antimicrobial effect and cosmetic composition comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090531 Year of fee payment: 16 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090531 Year of fee payment: 16 |